185
Views
13
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLECellular and Molecular Biology

Synergistic Effect of Celecoxib on TRAIL-induced Apoptosis in Hepatocellular Carcinoma Cells

, , , , &
Pages 629-634 | Published online: 15 Apr 2010

REFERENCES

  • Wiley, S.R.; Schooley, K.; Smolak, P.J.; Din, W.S.; Huang, C.P.; Nicholl, J.K., Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3(6), 673–682.
  • Pitti, R.M.; Marsters, S.A.; Ruppert, S.; Donahue, C.J.; Moore, A.; Ashkenazi, A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271(22), 12687–12690.
  • Ashkenazi, A.; Holland, P.; Eckhardt, S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008, 26(21), 3621–3630.
  • Almasan, A.; Ashkenazi, A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 2003, 14(3–4), 337–348.
  • Scaffidi, C.; Medema, J.P.; Krammer, P.H.; Peter, M.E. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J Biol Chem 1997, 272(43), 26953–26958.
  • Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V., et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388(6638), 190–195.
  • Xiao, C.; Yang, B.F.; Asadi, N.; Beguinot, F.; Hao, C. Tumor necrosis factor-related apoptosis-inducing ligand-induced death-inducing signaling complex and its modulation by c-FLIP and PED/PEA-15 in glioma cells. J Biol Chem 2002, 277(28), 25020–5025.
  • Yamanaka, T.; Shiraki, K.; Sugimoto, K.; Ito, T.; Fujikawa, K.; Ito, M., Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 2000, 32(3), 482–490.
  • Ganten, T.M.; Haas, T.L.; Sykora, J.; Stahl, H.; Sprick, M.R.; Fas, S.C., Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004, 11(Suppl. 1), S86–S96.
  • Steinbach, G.; Lynch, P.M.; Phillips, R.K.; Wallace, M.H.; Hawk, E.; Gordon, G.B., The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342(26), 1946–1952.
  • Kern, M.A.; Schubert, D.; Sahi, D.; Schoneweiss, M.M.; Moll, I.; Haugg, A.M., Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002, 36(4 Pt. 1), 885–894.
  • Wang, P.; Zhang, J.; Bellail, A.; Jiang, W.; Hugh, J.; Kneteman, N.M., Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal 2007, 19(11), 2237–2246.
  • Song, J.H.; Wang, C.X.; Song, D.K.; Wang, P.; Shuaib, A.; Hao, C. Interferon gamma induces neurite outgrowth by upregulation of p35 neuron-specific cyclin-dependent kinase 5 activator via activation of ERK1/2 pathway. J Biol Chem 2005, 280(13), 12896–12901.
  • Ganten, T.M.; Koschny, R.; Haas, T.L.; Sykora, J.; Li-Weber, M.; Herzer, K., et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 2005, 42(3), 588–597.
  • Liu, X.; Yue, P.; Zhou, Z.; Khuri, F.R.; Sun, S.Y. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004, 96(23), 1769–1780.
  • Song, J.H.; Song, D.K.; Herlyn, M.; Petruk, K.C.; Hao, C. Cisplatin downregulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. Clin Cancer Res 2003, 9(11), 4255–4266.
  • Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2), 74–108.
  • Skelton, M.R.; O'Neil, B. Targeted therapies for hepatocellular carcinoma. Clin Adv Hematol Oncol 2008, 6(3), 209–218.
  • Gajewski, T.F. On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol 2007, 25(11), 1305–1307.
  • Kim, Y.S.; Schwabe, R.F.; Qian, T.; Lemasters, J.J.; Brenner, D.A. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells. Hepatology 2002, 36(6), 1498–1508.
  • Liedtke, C.; Groger, N.; Manns, M.P.; Trautwein, C. Interferon-alpha enhances TRAIL-mediated apoptosis by upregulating caspase-8 transcription in human hepatoma cells. J Hepatol 2006, 44(2), 342–349.
  • Wu, G.S.; Burns, T.F.; McDonald, E.R., 3rd; Jiang, W.; Meng, R.; Krantz, I.D., KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997, 17(2), 141–143.
  • Song, J.H.; Song, D.K.; Pyrzynska, B.; Petruk, K.C.; Van Meir, E.G.; Hao, C. TRAIL triggers apoptosis in malignant glioma cells through extrinsic and intrinsic pathways. Brain Pathol 2003, 13(4), 539–553.
  • Zou, W.; Liu, X.; Yue, P.; Khuri, F.R.; Sun, S.Y. PPARgamma ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells. Cancer Biol Ther 2007, 6(1), 99–106.
  • Son, Y.G.; Kim, E.H.; Kim, J.Y.; Kim, S.U.; Kwon, T.K.; Yoon, A.R., Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 upregulation and downregulation of c-FLIP and survivin. Cancer Res 2007, 67(17), 8274–8284.
  • Bressac, B.; Galvin, K.M.; Liang, T.J.; Isselbacher, K.J.; Wands, J.R.; Ozturk, M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990, 87(5), 1973–1977.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.